In conjunction with the increased serum IL-10 levels seen in IFNβ treated MS patients [145,146], this indicates IL-10 modulation of macrophages and their monocyte precursors may occur in response to IFNβ treatment. The gene discussed is IFNB1; the disease is myeloid sarcoma.